Intermittent use of topical dimethyl sulfoxide in macular and papular amyloidosis.


Ozkaya-Bayazit E., Kavak A., Gungor H., Ozarmagan G.

International journal of dermatology, cilt.37, sa.12, ss.949-54, 1998 (SCI-Expanded) identifier identifier identifier

Özet

Background Severe and therapy-resistant pruritus is the most prominent feature of macular (MA) and lichen (LA) amyloidosis that leads to further amyloid deposition by recurrent frictional trauma to the epidermis. Of the various therapeutic modalities with variable success, the most encouraging and beneficial effect has been observed with topical dimethyl sulfoxide (DMSO) therapy. In a previous study, we achieved marked clinical improvement in nine of 10 patients in a daily treatment regimen over 6-20 weeks, but relapses occurred in the post-treatment follow-up period. The aims of this study are to investigate whether the patients would benefit from intermittent therapy and to determine the optimal application interval of DMSO to maintain the relief of symptoms.